Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 3
1996 1
1997 1
1999 1
2014 2
2015 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
HerzMobil Tirol network: rationale for and design of a collaborative heart failure disease management program in Austria.
Von der Heidt A, Ammenwerth E, Bauer K, Fetz B, Fluckinger T, Gassner A, Grander W, Gritsch W, Haffner I, Henle-Talirz G, Hoschek S, Huter S, Kastner P, Krestan S, Kufner P, Modre-Osprian R, Noebl J, Radi M, Raffeiner C, Welte S, Wiseman A, Poelzl G. Von der Heidt A, et al. Among authors: fluckinger t. Wien Klin Wochenschr. 2014 Nov;126(21-22):734-41. doi: 10.1007/s00508-014-0665-7. Epub 2014 Nov 13. Wien Klin Wochenschr. 2014. PMID: 25392254
Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study.
Willeit J, Geley T, Schöch J, Rinner H, Tür A, Kreuzer H, Thiemann N, Knoflach M, Toell T, Pechlaner R, Willeit K, Klingler N, Praxmarer S, Baubin M, Beck G, Berek K, Dengg C, Engelhardt K, Erlacher T, Fluckinger T, Grander W, Grossmann J, Kathrein H, Kaiser N, Matosevic B, Matzak H, Mayr M, Perfler R, Poewe W, Rauter A, Schoenherr G, Schoenherr HR, Schinnerl A, Spiss H, Thurner T, Vergeiner G, Werner P, Wöll E, Willeit P, Kiechl S. Willeit J, et al. Among authors: fluckinger t. Lancet Neurol. 2015 Jan;14(1):48-56. doi: 10.1016/S1474-4422(14)70286-8. Epub 2014 Nov 28. Lancet Neurol. 2015. PMID: 25435129
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M. Thaler J, et al. Among authors: fluckinger t. Leuk Res. 1997 Jan;21(1):75-80. doi: 10.1016/s0145-2126(96)00084-7. Leuk Res. 1997. PMID: 9029189 Clinical Trial.
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.
Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Sill H, Lang A, Falk M, Duba C, Utermann G, Kühr T, Aulitzky W, Huber C. Thaler J, et al. Among authors: fluckinger t. Ann Hematol. 1996 Jun;72(6):349-55. doi: 10.1007/s002770050185. Ann Hematol. 1996. PMID: 8767103 Clinical Trial.
Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.
Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Silly H, Lang A, Abbrederis C, Gadner H, et al. Thaler J, et al. Among authors: fluckinger t. Semin Hematol. 1993 Jul;30(3 Suppl 3):17-9. Semin Hematol. 1993. PMID: 8235697 Clinical Trial. No abstract available.